Douglas A. Colquhoun

Douglas A. Colquhoun

Auto-generated profile, based on publicly available information

Douglas A. Colquhoun

Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
DCDouglas A. Colquhoun
Douglas A. Colquhoun
ASAmy M. Shanks
Amy M. Shanks
SKSteven R. Kapeles
Steven R. Kapeles
NSNirav Shah
Nirav Shah
LSLeif Saager
Leif Saager
MMMichael R. Mathis
Michael R. Mathis
Use of the electronic health record (EHR) has become a routine part of perioperative care in the United States. Secondary use of EHR data includes research, quality, and educational initiatives. Fundamental to secondary use is a framework to ensure fidelity, transparency, and completeness of the source data. In developing this framework, competing priorities must be considered as to which data sources are used and how data are organized and incorporated into a useable format. In assembling perioperative data from diverse institutions across the United States and Europe, the Multicenter Perioperative Outcomes Group (MPOG) has developed methods to support such a framework. This special article outlines how MPOG has approached considerations of data structure, validation, and accessibility to support multicenter integration of perioperative EHRs. In this multicenter practice registry, MPOG has developed processes to extract data from the perioperative EHR; transform data into a standardized format; and validate, deidentify, and transfer data to a secure central Coordinating Center database. Participating institutions may obtain access to this central database, governed by quality and research committees, to inform clinical practice and contribute to the scientific and clinical communities. Through a rigorous and standardized approach to ensure data integrity, MPOG enables data to be usable for quality improvement and advancing scientific knowledge. As of March 2019, our collaboration of 46 hospitals has accrued 10.7 million anesthesia records with associated perioperative EHR data across heterogeneous vendors. Facilitated by MPOG, each site retains access to a local repository containing all site-specific perioperative data, distinct from source EHRs and readily available for local research, quality, and educational initiatives. Through committee approval processes, investigators at participating sites may additionally access multicenter data for similar initiatives. Emerging from this work are 4 considerations that our group has prioritized to improve data quality: (1) data should be available at the local level before Coordinating Center transfer; (2) data should be rigorously validated against standardized metrics before use; (3) data should be curated into computable phenotypes that are easily accessible; and (4) data should be collected for both research and quality improvement purposes because these complementary goals bolster the strength of each endeavor.

9 June 2022 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
DCDouglas A. Colquhoun
Douglas A. Colquhoun
MVMichelle T. Vaughn
Michelle T. Vaughn
LBLori D. Bash
Lori D. Bash
AJAllison Janda
Allison Janda
NSNirav Shah
Nirav Shah
SVShital Vachhani
Shital Vachhani

11 September 2024 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
NDNicholas J. Douville
Nicholas J. Douville
MSMark E. Smolkin
Mark E. Smolkin
BNBhiken I. Naik
Bhiken I. Naik
MMMichael Maile
Michael Maile
DCDouglas A. Colquhoun
Douglas A. Colquhoun
RSRobert B. Schonberger
Robert B. Schonberger

24 July 2021 in BMC Anesthesiology
Verified
Journal Article
Open access
PDF file
DCDouglas A. Colquhoun
Douglas A. Colquhoun
RDRyan P. Davis
Ryan P. Davis
TTTheodore T. Tremper
Theodore T. Tremper
JMJenny J. Mace
Jenny J. Mace
JGJan M. Gombert
Jan M. Gombert
KTKevin K. Tremper
Kevin K. Tremper
Background: Multifunction surveillance alerting systems have been found to be beneficial for the operating room and labor and delivery. This paper describes a similar system developed for in-hospital acute care environments, AlertWatch Acute Care (AWAC). Results: A decision support surveillance system has been developed which extracts comprehensive electronic health record (EHR) data including live data from physiologic monitors and ventilators and incorporates them into an integrated organ icon-based patient display. Live data retrieved from the hospitals network are processed by presenting scrolling median values to reduce artifacts. A total of 48 possible alerts are generated covering a broad range of critical patient care concerns. Notification is achieved by paging or texting the appropriated member of the critical care team. Alerts range from simple out of range values to more complex programing of impending Ventilator Associated Events, SOFA, qSOFA, SIRS scores and process of care reminders for the management of glucose and sepsis. As with similar systems developed for the operating room and labor and delivery, there are green, yellow, and red configurable ranges for all parameters. A census view allows surveillance of an entire unit with flashing or text to voice alerting and enables detailed information by windowing into an individual patient view including live physiologic waveforms. The system runs via web interface on desktop as well as mobile devices, with iOS native app available, for ease of communication from any location. The goal is to improve safety and adherence to standard management protocols. Conclusions: AWAC is designed to provide a high level surveillance view for multi-bed hospital units with varying acuity from standard floor patients to complex ICU care. Alerts are generated by algorithms running in the background and automatically notify the selected member of the patients care team. Its value has been demonstrated for low acuity patients, further study is required to determine its effectiveness in high acuity patients.

10 February 2025 in Anesthesiology
Verified
Journal Article
Closed access
RERania Elkhateb
Rania Elkhateb
DCDavis L. Campbell
Davis L. Campbell
XZXinyi Zhao
Xinyi Zhao
GMGraciela Mentz
Graciela Mentz
NSNadir El Sharawi
Nadir El Sharawi
TCthe Multicenter Perioperative Outcomes Group Perioperative Clinical Research Committee
the Multicenter Perioperative Outcomes Group Perioperative Clinical Research Committee
Background: Current practice guidelines do not address the use of neuromuscular blocking and antagonism agents in patients with renal impairment. The U.S. Food and Drug Administration (Silver Spring, Maryland) label for sugammadex advises against use in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 ml/min). Using a multicenter electronic health record registry, the authors sought to understand the modern use of neuromuscular blockade and antagonism agents in patients with significant renal impairment (eGFR less than 60 ml/min). Methods: Data were obtained from the Multicenter Perioperative Outcomes Group (MPOG) registry for adult patients (older than 18 yr) with an eGFR less than 60 ml/min, based on most recent serum creatinine, receiving general anesthesia for a nonrenal transplant procedure with an endotracheal tube between January 1, 2016, and July 31, 2022. Patients were classified into three mutually exclusive blockade and reversal strategies: rocuronium–sugammadex, cisatracurium–neostigmine, and rocuronium–neostigmine. Adjusted incidence of each blockade reversal strategy was established by a multinomial mixed effects model. The contribution of institution, anesthesiologist, and patient or case factors to variation in strategy choice was assessed by multilevel mixed effects models. Results: In 243,944 cases across 5,133 anesthesiologists and 48 institutions, adjusted use of rocuronium–sugammadex increased from 4.4 to 95.2%, rocuronium–neostigmine decreased from 84.7 to 4.3%, and cisatracurium–neostigmine decreased from 10.9 to 0.5%. In patients with an eGFR less than 15 ml/min, rocuronium–sugammadex use increased from 0.5 to 86.9%. Of the variation in choice of rocuronium–sugammadex versus cisatracurium–neostigmine, 30.1% was attributed to the institution, 22.7% to the attending anesthesiologist, and 47.2% to patient/case factors or was unexplained. The adjusted median odds ratio for this choice was 2.5 for clinicians and 3.1 for institutions. Conclusion: Rocuronium–sugammadex is the primary neuromuscular blockade–antagonism strategy for patients with moderate and severe renal impairment. Variation in choice is significantly impacted by the institution and attending anesthesiologist providing care.

17 April 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
BPBethany R Tellor Pennington
Bethany R Tellor Pennington
DCDouglas A Colquhoun
Douglas A Colquhoun
MNMark D Neuman
Mark D Neuman
MPMary C Politi
Mary C Politi
AJAllison M Janda
Allison M Janda
SKSachin Kheterpal
Sachin Kheterpal
Introduction Millions of patients receive general anaesthesia for surgery annually. Crucial gaps in evidence exist regarding which technique, propofol total intravenous anaesthesia (TIVA) or inhaled volatile anaesthesia (INVA), yields superior patient experience, safety and outcomes. The aim of this pilot study is to assess the feasibility of conducting a large comparative effectiveness trial assessing patient experiences and outcomes after receiving propofol TIVA or INVA. Methods and analysis This protocol was cocreated by a diverse team, including patient partners with personal experience of TIVA or INVA. The design is a 300-patient, two-centre, randomised, feasibility pilot trial. Patients 18 years of age or older, undergoing elective non-cardiac surgery requiring general anaesthesia with a tracheal tube or laryngeal mask airway will be eligible. Patients will be randomised 1:1 to propofol TIVA or INVA, stratified by centre and procedural complexity. The feasibility endpoints include: (1) proportion of patients approached who agree to participate; (2) proportion of patients who receive their assigned randomised treatment; (3) completeness of outcomes data collection and (4) feasibility of data management procedures. Proportions and 95% CIs will be calculated to assess whether prespecified thresholds are met for the feasibility parameters. If the lower bounds of the 95% CI are above the thresholds of 10% for the proportion of patients agreeing to participate among those approached and 80% for compliance with treatment allocation for each randomised treatment group, this will suggest that our planned pragmatic 12 500-patient comparative effectiveness trial can likely be conducted successfully. Other feasibility outcomes and adverse events will be described. Ethics and dissemination This study is approved by the ethics board at Washington University (IRB# 202205053), serving as the single Institutional Review Board for both participating sites. Recruitment began in September 2022. Dissemination plans include presentations at scientific conferences, scientific publications, internet-based educational materials and mass media. Trial registration number NCT05346588.